Author: Caplan Liron Saag Kenneth G
Publisher: Informa Healthcare
ISSN: 1474-0338
Source: Expert Opinion on Drug Safety, Vol.8, Iss.1, 2009-01, pp. : 33-47
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Increased CV risk with glucocorticoids in Cushing's
Reactions Weekly, Vol. 1, Iss. 1413, 2012-01 ,pp. :
Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis
By Cranney Ann
Drug Safety, Vol. 28, Iss. 8, 2005-01 ,pp. :
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis
Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. :